Dihydropyranopyrimidines for the treatment of viral infections

Patent metadata

Field	Value
Publication number	US-2021387997-A1
Application number	US-202117355864-A
Country	US
Kind code	A1
Filing date	Jun 23, 2021
Priority date	Jul 1, 2016
Publication date	Dec 16, 2021
Grant date	—

Abstract

This invention relates to dihydropyranopyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

First claim

1 . A compound of formula (I):

or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein
R 1 is C 1-6 alkyl optionally substituted by one or more substituents independently selected from hydroxyl or C 1-3 alkoxy;
R 2 is selected from hydrogen, fluorine, C 1-3 alkyl, cyclopropyl, —CF 3 , C 1-3 alkoxy or nitrile.

2 - 5 . (canceled)

6 . The compound of claim 1 , wherein R 1 is C 1-6 alkyl substituted by hydroxyl.

7 . The compound of claim 6 , wherein R 1 is:

8 . The compound of claim 1 , wherein R 2 is hydrogen.

9 . The compound of claim 1 , having the following structure:

10 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

11 . A compound of formula (II):

or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein
R 1 is C 1-6 alkyl optionally substituted by one or more substituents independently selected from hydroxyl or C 1-3 alkoxy;
R 2 is selected from hydrogen, fluorine, C 1-3 alkyl, cyclopropyl, —CF 3 , C 1-3 alkoxy or nitrile.

12 . The compound of claim 11 , wherein R 1 is C 1-6 alkyl substituted by hydroxyl.

13 . The compound of claim 12 , wherein R 1 is:

14 . The compound of claim 11 , wherein R 2 is hydrogen.

15 . The compound of claim 11 , having the following structure:

16 . A pharmaceutical composition comprising the compound of claim 11 , or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

17 . A compound of formula (III):

or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein
R 1 is C 1-6 alkyl optionally substituted by one or more substituents independently selected from hydroxyl or C 1-3 alkoxy;
R 2 is selected from hydrogen, fluorine, C 1-3 alkyl, cyclopropyl, —CF 3 , C 1-3 alkoxy or nitrile.

18 . The compound of claim 17 , wherein R 1 is C 1-6 alkyl substituted by hydroxyl.

19 . The compound of claim 18 , wherein R 1 is:

20 . The compound of claim 17 , wherein R 2 is hydrogen.

21 . The compound of claim 17 , having the following structure:

22 . A pharmaceutical composition comprising the compound of claim 17 , or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Assignees

• Janssen Sciences Ireland Unlimited Co

Inventors

• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard
• Guillemont Jérôme Émile Georges
• Mc Gowan David Craig
• Embrechts Werner Constant Johan
• Cooymans Ludwig Paul
• Calmus Laurent

Classifications

• C07D491/052 Primary

  the oxygen-containing ring being six-membered · CPC title

• A61P31/02

  Local antiseptics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title